OA13332A - Pyrimidin-4-one derivatives and their use as P38 kinase modulators. - Google Patents

Pyrimidin-4-one derivatives and their use as P38 kinase modulators. Download PDF

Info

Publication number
OA13332A
OA13332A OA1200600180A OA1200600180A OA13332A OA 13332 A OA13332 A OA 13332A OA 1200600180 A OA1200600180 A OA 1200600180A OA 1200600180 A OA1200600180 A OA 1200600180A OA 13332 A OA13332 A OA 13332A
Authority
OA
OAPI
Prior art keywords
alkyl
oxy
methyl
difluorobenzyl
bromo
Prior art date
Application number
OA1200600180A
Other languages
English (en)
Inventor
Balenkundru Devadas
Richard Durley
Brian Hickory
Heather Madsen
Katherine Palmquist
Shaun Selness
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Priority to OA1200600180A priority Critical patent/OA13332A/en
Publication of OA13332A publication Critical patent/OA13332A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (17)

  1. 013332 346 What is claimed is:
    or a pharmaceutically acceptable sait thereof, wherein L and M are independently selected from -O-, -CH2-, -S-, -N(R)-N(R)-, C(=O)-, - SO2-;
    Xi, X2, Xa, Xb, Xc, Xd, and Xe at are independently selected from -C(O)NReR7, -(C1-C4 alkyl)-C(O)NRiR7, -NReRï, hydroxy(Ci-C4)alkyl, C1-C4 dihydroxyalkyl, H,halogen, haloalkyl, alkyl, haloalkoxy, heteroaiyl, heterocycloalkyl, C3-C7 cycloalkyl,R«R7N-(Ci-C6 alkyl)-, -CO2-(CrC6)alkyl, -N(R)C(O)NReR7, -N(R)C(O)-(CI-Ce)alkoxy,CO2R-(Ci-C6 alkyl)-, or -SO2NReR7, wherein the heteroaryl and heterocycloalkyl groupsare optionally substituted with -NRéR7, -C(O)NR<R7, R«R7N-(Ci-C6 alkyl)-, Ci-Ce alkyl,Ci-Cô alkoxy, or halogen; or R5 is heteroaryl or heteroarylalkyl, wherein the heteroaryl and heteroaryl groupsare optionally substituted with 1,2, 3, or 4 groups that are independently -C(O)NRîR7, -(C1-C4 alkyl)-C(O)NReR7, -NReR?, hydroxy(Ci-C4)alkyl, C1-C4 dihydroxyalkyl, H, OH,halogen, haloalkyl, alkyl, haloalkoxy, ReR7N-(Ci-C6 alkyl)-, -CO2-(Ci-Ce)alkyl,-N(R)C(O)NReR7, or -N(R)C(O)-(Ci-C6)alkoxy; wherein Re and R7 are independently at each occurrence H, Ci-Cô alkyl, Ci-Ce alkoxy, Ci-C6 alkoxy Ci-C6 alkyl, Cj-Cé alkoxycarbonyl, OH, Ci-Ce hydroxyalkyl, C1-C4 013332 347 dihydroxyalkyl, Ci-Cé thiohydroxyalkyl, -(Ci-C4)alkyl-CO2-alkyl, pyridyl C]-Cc alkyl,Ci-Cê alkanoyl, benzyl, phenyl C1-C6 alkoxy, or phenyl Ci-Cé alkanoyl, wherein each ofthe above is unsubstituted or substituted with 1, 2, or 3 groups that are independently,halogen, C3-Ce cycloalkyl, Ci-Cé alkoxy, piperidinyl Cj-Cg alkyl, morpholinyl Ci-Cgalkyl, piperazinyl Ci-C6 alkyl, OH, SH, NH2, NH(alkyl), N(alkyl)(alkyl), -O-C1-C4alkanoyl, C1-C4 alkyl, CF3, or OCF3; or Ré, R7, and the nitrogen to which they are attached form a morpholinyl,thiomorpholinyl, piperidinyl, pyrrolidinyl, or piperazinyl ring which is optionallysubstituted with 1 or 2 groups that are independently C1-C4 alkyl, CÎ-C4 alkoxy, hydroxy,hydroxy C1-C4 alkyl, C1-C4 dihydroxyalkyl, or halogen; R at each occurrence is independently H or Ci-Cé alkyl; and Y, Yi, Y2, Y3, and Y4 are independently selected from H, halogen, alkyl,carboxaldehyde, hydroxyalkyl, dihydroxyalkyl, alkenyl, alkynyl, CN, alkanoyl, alkoxy,alkoxyalkyl, haloalkyl, and carboxyl.
  2. 2. The compound according to claim 1 of the formula
    or a pharmaceutically acceptable sait thereof.
  3. 3. The compound according to claim 8, wherein R5 is a heteroaryl or heteroarylalkyl group, where each heteroaryl is pyrazolyl, imidazolyl, furanyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, imidazolyl,dihydroindolyl, dihydroisoindolyl, indolon-2-yl, quinolinyl, isoquinolinyl,tetrahydroisoquinolinyl, dihydroisoquinolinyl, or indolyl, each of which is optionallysubstituted with 1, 2, 3, or 4 groups that are independently -C(O)NRéR7, -(C1-C4 alkyl)-C(O)NRéR7, -NRéR?, hydroxy(Ci-C4)alkyl, C1-C4 dihydroxyalkyl, hydrogen, hydroxy, 013332 348 halogen, haloalkyl, alkyl, haloalkoxy, ReR7N-(Ci-Cg alkyl)-, -CO2-(Ci-C6)alkyl,-N(R)C(O)NReR7, or -N(R)C(O)-(Ci-Ce)alkoxy; wherein Re and R7 are independently at each occurrence H, Ci-Ce alkyl, Ci-Cé alkoxy, Ci-Câ alkoxy Ci-Cô alkyl, Ci-Ce alkoxycarbonyl, OH, Ci-Ce hydroxyalkyl, Ci-Câdihydroxyalkyl, Cj-Cî thiohydroxyalkyl, -(Ci-C4)alkyl-CO2-alkyl, pyridyl Cj-Cé alkyl,Ci-Cê alkanoyl, benzyl, phenyl Ci-Ce alkoxy, or phenyl Ci-Ce alkanoyl, wherein each ofthe above is unsubstituted or substituted with 1, 2, or 3 groùps that are independently,halogen, C3-C6 cycloalkyl, C1-C6 alkoxy, piperidinyl Ci-Ce alkyl, morpholinyl Ci-Cealkyl, piperazinyl Ci-Ce alkyl, OH, SH, NH2, NH(alkyl), N(alkyl)(alkyl), -O-C1-C4alkanoyl, C1-C4 alkyl, CF3, or OCF.
  4. 4. The compound according to claim 3, wherein Y2, Y4, and Y are independently halogen; and Yi and Y3 are both hydrogen.
  5. 5. The compound according to claim 4, wherein Xi and X2 are independently H, methyl, -NR^R?, R6R7N-(Ci-C6 alkyl)-, -C(0)NRîR7, -(C1-C4 alkyl)-C(O)NReR7, Ci-C6 hydroxyalkyl, C1-C5 dihydroxyalkyl, or -(C1-C4 alkyl)-morpholinyl.
  6. 6. The compound according to claim 5, wherein R5 is pyridyl Ci-Cé alkyl, pyrimidinyl Ci-Câ alkyl, or pyrazinyl Ci-Câ alkyl, eachof which is optionally substituted with 1, 2, or 3 groups that are independentlyhydroxy(Ci-C4)alkyl, C1-C4 dihydroxyalkyl, OH, halogen, CF3, (Ci-C4)alkyl, OCF3,-NReR7, -(C1-C4 alkyI)-C(O)NR6R7, R^N-CCi-G alkyl)-, or -C(O)NRîR7.
  7. 7. A compound according to claim 2, wherein Xa Xe Xb ψ Xd Rs is or Xb' Xa Xd Xe Xc 013332 349
  8. 8. The compound according to claim 7, wherein Xa is hydrogen; two of Xb, Xc> and Xd are hydrogen and the other is -C(O)NRîR7, -(Ci-Cô alkyl)-C(O)NRôR7, -NRôRî, R6R7N-(Ci-C6 alkyl)- or -CO2-(Ci-Cô)alkyl; wherein Rô and R7 are independently at each occurrence H, Ci-Cô alkyl, Ci-Cô alkoxy, Ci-Ce alkoxy Ci-Cs alkyl, Ci-Cô alkoxycarbonyl, OH, Ci-Ci hydroxyalkyl, Ci-Cedihydroxyalkyl, -(Cj-C4)alkyl-CO2-alkyl, pyridyl Ci-C<s alkyl, Ci-C6 alkanoyl, benzyl,phenyl Ci-Cg alkoxy, or phenyl Ci-Ce alkanoyl, wherein each of the above isunsubstituted or substituted with 1, 2, or 3 groups that are independently, halogen, C3-C6cycloalkyl, Cj-Ce alkoxy, piperidinyl Ci-Cô alkyl, morpholinyl Ci-Cô alkyl, piperazinylCi-C6 alkyl, OH, NH2, NH(alkyl), N(alkyl)(alkyl), -O-C1-C4 alkanoyl, C1-C4 alkyl, CF3,or OCF3; or Rô, R7, and the nitrogen to which they are attached form a morpholinyl,piperidinyl, pyrrolidinyl, or piperazinyl ring which is optionally substituted with 1 or 2groups that are independently C1-C4 alkyl, C1-C4 alkoxy, hydroxy, hydroxy C1-C4 alkyl,C1-C4 dihydroxyalkyl, or halogen; and Xe is hydrogen, methyl, C1-C2 alkoxy, or halogen.
  9. 9. The compound according to claim 8, wherein Xb is -C(O)NRôR7, -(Ci-C6 alkyl)-C(O)NRôR7, -NRôR7, or RôR-zN-ÎCî-Cs alkyl)-wherein Rî is hydrogen or C1-C4 alkyl; R7 is OH, Ci-Ci alkyl or C1-C5 alkanoyl, wherein the alkyl and alkanoyl groupssubstituted with 1, 2, or 3 groups that are independently NH2, NH(Ci-Cô alkyl), N(Ci-Cealkyl)(Ci-Ce alkyl), C3-C6 cycloalkyl, OH, or C1-C4 alkoxy.
  10. 10. The compound according to claim 7, wherein Xa is halogen or methyl; Xb is H, -NRôR7, RôR7N-(Ci-C6 alkyl)-, -C(O)NRôR7, or -CO2-(C,-C6)alkyl, 013332 350 Xo is -NR«R7, RîR7N-(Ci-C6 alkyl)-, -C(O)NR6R7, halogen, -CO2-(Ci-C«)alkyl,NH2, NH(C,-C6 alkyl), N(CrC6 alkyl)(Ci-C6 alkyl), -SO2NH2, -SO2NH(Ci-C6 alkyl), -SO2N(Ci-Ce alkyl)(Ci-Cô alkyl), or piperazinyl, wherein the piperazinyl group isoptionally substituted with 1 or 2 groups that are independently C1-C4 alkyl, C1-C4alkoxy, hydroxy, hydroxy C4-C4 alkyl, C1-C4 dihydroxyalkyl, or halogen; Xd is hydrogen; and Xe is H, methyl, NH2, NH(Ci-C6 alkyl) or N(Ci-C6 alkyl)(Ci-C6 alkyl).
  11. 11. The compound according to claim 7, wherein Xi, X2, Xa, Xb, Xc, Xa, and Xe are independently selected from H, OH, halogen,CF3, alkyl, OCF3, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, thienyl, furyl, pyrrolyl,piperidinyl, piperazinyl, or C3-C7 cycloalkyl, wherein each of the above is optionallysubstituted with -NRôR7, -C(O)NRîR7, -(C1-C4 alkyl)-C(O)NRôR7, R«R7N-(Ci-C6 alkyl)-,Ci-Cg alkyl, Ci-Ce alkoxy, or halogen.
  12. 12. The compound according to claim 7 selected from the group consisting of: 3-[5-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-N,4-dimethylbenzamide; Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-4-methylbenzoate; Methyl 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-4-methylbenzoate; 3-[5-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-4-methylbenzamide; 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-(methylthio)-6-oxopyrimidin-l(6H)-yl]-4-methylbenzamide; 3-[5-chloro-4-[(2,4-difluorobenzyl)oxyJ-6-oxopyrimidin-l(6H)-yl]-4- methylbenzamide; . (±) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-4-methyl-N-{ 1 -[(methylamino)carbonyl]methyl}benzamide; 013332 351 (-) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-4-methyl-N- {1 -[(methylamino)carbonyl]raethyl} benzamide; (+) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-4-methyl-N- {1 -[(methylamino)carbonyl]methyl} benzamide; (-) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrîmidin-l(6H)-yl]-4-methylbenzamide; (+)3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-4- methylbenzamide; (-) 3-[5-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-N,4-dimethylbenzamide; (+) 3-[5-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-rriethyl-6-oxopyrimidin-l(6H)-yl]-N,4-dimethylbenzamide; (-) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-4-methyl-N-{ 1 -[aminocarbonyl]methyl} benzamide; (+) 3 -[5 -bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1 (6H)-yl]-4-methyl-N-{ 1 -[aminocarbonyl]methyl}benzamide; (±) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-N-[(2S)-2,3-dihydroxypropyl]-4-methylbenzamide; (-)3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]- N-[(2iS)-2,3-dihydiOxypropyl]-4-methylbenzamide; 013332 352 (+) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl] N-[(25)-2,3 -dihydroxypropyl]-4-methylbenzamide; (+) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]N-[(2A)-2,3-dihydroxypropyl]-4-methylbenzamide; (-) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l (6H)-ylj-N-[(2A)-2,3-dihydroxypropyl]-4-methylbenzamide; (+) 3-[5-bromo-4-[(2,4-dÎfluorobenzyl)oxy]-2-meîhyl-6-oxopyrimidin-l(6H)-yl]N-[(2/?)-2,3-dihydroxypropyl]-4-methylbenzamide; (+) N-[(l S)-l -(aminocarbonyl)ethyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-4-methylbenzamide; (-) N-[(lS)-l-(aminocarbonyl)ethyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1 (6H)-yl]-4-methylbenzamide; (+) N-[(l S)-l -(aminocarbonyl)ethyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1 (6H)-yl]-4-methylbenzamide; (±) 3-(5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]N-[(l R)-2-hydroxy-1 -methylethyl]-4-methylbenzamide; (±) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidÎn-l(6H)-yl]N-[(l S)-2-hydroxy-l -methylethyl]-4-methylbenzamide; (±)3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyI-6-oxopyrimidin-l(6H)-yl]- N-[(2S)-2-hydroxypropyl]-4-methylbenzamide; 013332 353 (-)3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyriniidin'l(6H)-yl]- N-[(2S)-2-hydroxypropyl]'4-methylbenzamide; (+)3-[5-bromo-4-[(2)4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]- N-[(2S)-2-hydroxypropyl]-4-methylbenzamide; (±)3-[5-bromo-4-[(234-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]- N-[(2R)-2-hydroxypropyl]-4-methylbenzamide; (-)3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]- N-[(2R)-2-hydroxypropyl]-4-methylbenzainide; (+)3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]- N-[(2R)-2-hydroxypropyl]-4-methylbenzamide; (±) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-N-(2-hydroxyeîhyl)-4-methylbenzamide; (-) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyI-6-oxopyrimidin-l(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide; (+) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyriniidin-l (6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide; (±) N-[(l S)-l -(aminocarbonyl)propyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-4-methylbenzamide; (-) N-[(lS)-l-(aminocarbonyl)propyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-4-methylbenzamide; 013332 354 (+) N-[(l S)-l -(aminocarbonyl)propyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2- methyl-6-oxopyrimidin-1 (6H)-yl]-4-methylbenzamide; 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl}-N-[l-(amin ocarbony l)methy 1] -4-methylbenzamide ; 3-[4-[(2,4"difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-4-methylbenzoate; 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-4-methyl-N-{1 -[(methylamino)carbonyl]methyl} benzamide; 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-N-[(2S)-2,3- dihydroxypropyl]-4-methylbenzamide; N-[(lS)-l-(aminocarbonyl)ethyl]-3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1 (6H)-yl]-4-methylbenzamide; 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-N-[(lS)-2-hydroxy-1 -methylethyI]-4-methyibenzamide; 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-N-(2- hydroxyethyl)-4-methylbenzamide; 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-N-[(lR)-2-hydroxy-1 -methylethyl]-4-methylbenzamide; 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-N-[l- (aminocarbonyl)methyI]-N,4-dimethylbenzamide; 013332 355 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-N-[(2R)-2,3- dihydroxypropyl]-4-methylbenzamide; N-[(lR)-l-(aminocarbonyl)-2-hydroxyethyl]-3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1 (6H)-yl] -4-methylbenzamide; N-[(lR)-l-(aminocarbonyl)ethyI]-3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1 (6H)-yl]-4-methylbenzamide; 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l (6H)-yl]-N-[(l S)-2-hydroxy-1-methylethyl]-4-methylbenzamide; 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-N-[(lR)-2-hydroxy-1 -methylethyl]-4-methylbenzamide; 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-N,4- dimethylbenzamide; N-[ 1 -(ammocarbonyl)methyl]-3 -[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1 (6H)-yl]-4-methylbenzamide; N-[(lR)-l-(aminocarbonyl)ethyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6- oxopyrimidin-l(6H)-yl]-4-methylbenzamide; N-[(lS)-l-(aminocarbonyl)propyl]-3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1 (6H)-yl]-4-methylbenzamide; 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-N-[(2S)-2- hydroxypropyl]-4-methylbenzamide; 013332 356 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-N-[(2R)-2- hydroxypropyl]-4-methylbenzamide; 5-chloro-6-[(2,4-difluorobenzyl)oxy]-3-(5-{[(3S)-3-hydroxypyrrolidin-l-yl]carbonyl}-2-methylphenyl)pyrimidin-4(3H)-one; ' 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-N-(2- methoxyethyl)-4-methylbenzamide; 5-chloro-6-[(2,4-difIuorobenzyl)oxy]-3-(5 - {[(3 R)-3-hydroxypyrrolidin-1 -yljearbonyl} -2-methylphenyl)pyrimidin-4(3H)-one; 3-[4-[(2,4-difluorobenzyl)oxy]-5-ethyl-6-oxopyrimidin-l(6H)-yl]-N-[(lR)-2-hydroxy-1 -meihylethyl]-4-methylbenzamide; methyl 3-[4-[(2,4-difluorobenzyl)oxy]-5-iodo-6-oxopyrimidin-l(6H)-yl]-4-methylbenzoate, methyl 3-[4-[(2î4-difluorobenzyl)oxy]-5-ethyl-6-oxopyrimidin-l(6H)-yl]-4-methylbenzoate; 3-[4-[(2,4-difluorobenzyl)oxy]-5-ethyl-6-oxopyrimidin-l(6H)-yl]-N-(2- hydroxyethyl)-4-methylbenzamide; 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-(methylamino)-6-oxopyrimidin-l(6H) yl]-N,4-dimethylbenzamide; methyl 3-[5-bromo-4-[(2,4-difluorobenzyl)o?Q']-2-(methylamino)-6-oxopyrimÎdin-l(6H)yl]-4-methylbenzoate; 013332 357 N-[l-(aminocarbonyl)methyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2- (methylamino)-6-oxopyrÎmidin-l(6H)-yl]-4-methylbenzamide; 3-[5-bromo-4-[(2,4-dï£luorobenzyl)oxy]-2-(methylainÎno)-6-oxopyrimidin-l(6H)- yl]-N-[(2S)-2,3-dihydroxypropyl]-4-methylbenzamide; 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-4-methyl-N-{1 - [(methylamino)carbonyl]methyl} benzamide; 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-N-[(2S)-2,3- dihydroxypropyl]-4-methylbenzamide; 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-N-[(2R)-2,3- dihydroxypropyl]-4-methylbenzamide; 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-N-(2- hydroxyethyl)-4-methylbenzamide; N-[(lS)-l-(aminocarbonyI)ethyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimid in-1 (6H)-yl] -4-methylbenzamide; 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-N-[(2S)-2- hydroxypropyl]-4-methylbenzamide; 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-l(6H)-yl]-N-[(2R)-2- hydroxypropyl]-4-methylbenzamide; (±) 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]- N-(2-hydroxyethyl)-4-methylbenzamide; 013332 358 (-) 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]- N-(2-hydroxyethyl)-4-methylbenzamide; (+) 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopynmidin-l(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide; (±) 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-4-methyl-N- {1 -[aminocarbonyl]methyl} benzamide; (-)3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-4methyl-N- {1 -[aminocarbonyljmethyl} benzamide; (±) 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-ylj-4-methyl-N- {1 -[(methylamino)carbonyl]methyl} benzamide; (±) 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-ylj-4-methyl-N- {1 -[(methylamino)carbonyljmethyl} benzamide; ± 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-N[(2S)-2-hydroxypropyl]-4-methylbenzamide; ± 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]-N[(2R)-2-hydroxypropyl]-4-methylbenzamide; 3- benzyl-6-(benzyloxy)-5-bromopyrimidin-4(3H)-one; 3 -benzyl-6-(benzyloxy)-pyrimidin-4(3H)-one; 4- {[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l(6H)-yl]methyl}-N-methylbenzamide; and methyl 4-{[4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-l (6H)-y 1 ]methyl} benzo ate; 013332 359 or their isomer and pharmaceutically acceptable sait thereof.
  13. 13. A pharmaceutical composition comprising a compound of claiml2, or apharmaceutically acceptable sait or tautomer thereof.
  14. 14. Use of a compound of Claim 12, or a pharmaceutically acceptable sait or tautomerthereof in the manufacture of a médicament for treating arthritis in a subject.
  15. 15. Use of a compound of Claim 12, or a pharmaceutically acceptable sait or tautomerthereof, in the manufacture of a médicament for treating rheumatoid arthritis in a subject.
  16. 16. Use of a compound of Claim 12, or a pharmaceutically acceptable sait or tautomerthereof in the manufacture of a médicament for treating asthma in a subject.
  17. 17. Use of a compound of Claim 12, or a pharmaceutically acceptable sait or tautomerthereof in the manufacture of a médicament for treating chronic obstructive pulmonarydisease (COPD) in a subject..
OA1200600180A 2006-06-02 2006-06-02 Pyrimidin-4-one derivatives and their use as P38 kinase modulators. OA13332A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
OA1200600180A OA13332A (en) 2006-06-02 2006-06-02 Pyrimidin-4-one derivatives and their use as P38 kinase modulators.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
OA1200600180A OA13332A (en) 2006-06-02 2006-06-02 Pyrimidin-4-one derivatives and their use as P38 kinase modulators.

Publications (1)

Publication Number Publication Date
OA13332A true OA13332A (en) 2007-04-13

Family

ID=43969346

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200600180A OA13332A (en) 2006-06-02 2006-06-02 Pyrimidin-4-one derivatives and their use as P38 kinase modulators.

Country Status (1)

Country Link
OA (1) OA13332A (fr)

Similar Documents

Publication Publication Date Title
AU2004226165B2 (en) Pyrimidin-4-one derivatives and their use as p38 kinase modulators
US7795271B2 (en) Substituted pyrimidinones
CA2476012C (fr) Pyridinones substituees servant de modulateurs de la map kinase p38
JP5487214B2 (ja) キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
MXPA05005270A (es) Nuevos derivados de piridazinona como productos farmaceuticos y composiciones farmaceuticas que los contienen.
JP2001526230A (ja) ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用
SK92798A3 (en) Novel substituted imidazole compounds
JP2009523797A (ja) 炎症性障害の処置のためのヒダントイン化合物
TW200840580A (en) Heterocyclic aspartyl protease inhibitors
JP2000509719A (ja) 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
JP2000514806A (ja) プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
JP2002105047A (ja) サイトカインとして有用なある種の１，４，５−三置換イミダゾール化合物ならびにその製造に使用される化合物
WO2003029210A2 (fr) Composes de tetrazole substitues par heteroaryle, modulateurs du recepteur-5 metabotropique du glutamate
KR20010083055A (ko) 글리코겐 신타제 키나제 3의 억제제
CZ218198A3 (cs) Nové cykloalkylem substituované imidazoly, způsob jejich přípravy, farmaceutické prostředky s jejich obsahem a způsob inhibice
WO2012149528A1 (fr) Inhibiteurs de la forme inductible de la 6-phosphofructose-2-kinase
KR20180067678A (ko) 피리미딘 유도체
CN105658644B (zh) 取代咪唑用作n型钙通道阻滞剂
OA13332A (en) Pyrimidin-4-one derivatives and their use as P38 kinase modulators.
WO2021110574A1 (fr) Inhibiteurs d&#39;alcynyle- (hétéroaryl)-carboxamide hcn1
BG63362B1 (bg) Нови заместени имидазоли
HK1030211A (en) 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors